Frequently Asked Questions
Clinical Next-Generation Sequencing (NSG) Testing Market to grow at a CAGR 27.25% by forecast 2028.
North America region holds the largest share in the market.
The major players covered in the clinical next-generation sequencing (NSG) testing market report are 3billion, Inc., 10x Genomics., 23andMe, Inc., Adaptive Biotechnologies., Admera Health, Agilent Technologies, Inc., ALCEN, Almac Group, AMARANTUS BIOSCIENCE HOLDINGS, INC., Ambry Genetics., Aperiomics, Inc., ARUP Laboratories., ASURAGEN, INC., Athena Diagnostics, Inc., Atreca, Inc., Base4, Baylor Genetics, BD, Berry Gene, BGI, Bioarray S.L, Biodesix., Boreal Genomics Inc. and Cambridge Epigenetix Limited.
The countries covered in the clinical next-generation sequencing (NSG) testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
